Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil

AbstractInvasive fungal disease (IFD) shows distinct regional incidence patterns and epidemiological features depending on the geographic region. We conducted a prospective survey in eight centres in Brazil from May 2007 to July 2009. All haematopoietic cell transplant (HCT) recipients and patients with acute myeloid leukaemia (AML) or myelodysplasia (MDS) were followed from admission until 1 year (HCT) or end of consolidation therapy (AML/MDS). The 12-month cumulative incidence (CI) of proven or probable IFD was calculated, and curves were compared using the Grey test. Among 237 AML/MDS patients and 700 HCT recipients (378 allogeneic, 322 autologous), the 1-year CI of IFD in AML/MDS, allogeneic HCT and autologous HCT was 18.7%, 11.3% and 1.9% (p <0.001), respectively. Fusariosis (23 episodes), aspergillosis (20 episodes) and candidiasis (11 episodes) were the most frequent IFD. The 1-year CI of aspergillosis and fusariosis in AML/MDS, allogeneic HCT and autologous HCT were 13.4%, 2.3% and 0% (p <0.001), and 5.2%, 3.8% and 0.6% (p 0.01), respectively. The 6-week probability of survival was 53%, and was lower in cases of fusariosis (41%). We observed a high burden of IFD and a high incidence and mortality for fusariosis in this first multicentre epidemiological study of IFD in haematological patients in Brazil

Cytogenetic studies of Brazilian pediatric myelodysplastic syndrome cases: challenges and difficulties in a large and emerging country

Myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematopoietic stem cell diseases affecting children. Cytogenetics plays an important role in the diagnosis of these diseases. We report here the experience of the Cytogenetic Subcommittee of the Brazilian Cooperative Group on Pediatric Myelodysplastic Syndromes (BCG-MDS-PED). We analyzed 168 cytogenetic studies performed in 23 different cytogenetic centers; 84 of these studies were performed in patients with confirmed MDS (primary MDS, secondary MDS, JMML, and acute myeloid leukemia/MDS+Down syndrome). Clonal abnormalities were found in 36.9% of the MDS cases and cytogenetic studies were important for the detection of constitutional diseases and for differential diagnosis with other myeloid neoplasms. These data show the importance of the Cooperative Group for continuing education in order to avoid a late or wrong diagnosis

Guidelines On The Diagnosis And Treatment For Acute Promyelocytic Leukemia: Associação Brasileira De Hematologia, Hemoterapia E Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013

[No abstract available]3617192Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, , IARC: LyonRohr, S.S., Pelloso, L.A., Borgo, A., de Nadai, L.C., Yamamoto, M., Rego, E.M., Chauffaille, M.L., Acute promyelocytic leukemia associated with the PLZF-RARA fusion gene: Two additional cases with clinical and laboratorial peculiar presentations (2012) Med Oncol, 29 (4), pp. 2345-2347De Lourdes, C.M., Borri, D., Proto-Siqueira, R., Moreira, E.S., Alberto, F.L., Acute promyelocytic leukemia with t(15;17): Frequency of additional clonal chromosome abnormalities and FLT3 (2008) Leuk Lymphoma, 49 (12), pp. 2387-2389Gupta, S.K., Sazawal, S., Mahapatra, M., Saxena, R., Evaluation of PG-M3 antibody in the diagnosis of acute promyelocytic leukaemia (2010) Eur J Clin Invest, 40 (10), pp. 960-962Dimov, N.D., Medeiros, L.J., Kantarjian, H.M., Cortes, J.E., Chang, K.S., Bueso-Ramos, C.E., Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: The M.D (2010) Cancer, 116 (2), pp. 369-376. , Anderson Cancer Center experience of 349 patientsBrockman, S.R., Paternoster, S.F., Ketterling, R.P., Dewald, G.W., New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia (2003) Cancer Genet Cytogenet, 145 (2), pp. 144-151O'Connor, S.J., Forsyth, P.D., Dalal, S., Evans, P.A., Short, M.A., Shiach, C., The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody (1997) Br J Haematol, 99 (3), pp. 597-604Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet (2009) Blood, 113 (9), pp. 1875-1891Tallman, M.S., Altman, J.K., How I treat acute promyelocytic leukemia (2009) Blood, 114 (25), pp. 5126-5135Chang, H., Kuo, M.C., Shih, L.Y., Dunn, P., Wang, P.N., Wu, J.H., Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia (2012) Eur J Haematol, 88 (4), pp. 321-328Kim, D.Y., Lee, J.H., Lee, J.H., Kim, S.D., Lim, S.N., Choi, Y., Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia (2011) Leuk Res, 35 (2), pp. 152-158Yanada, M., Matsushita, T., Asou, N., Kishimoto, Y., Tsuzuki, M., Maeda, Y., Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: Incidence, risk factors, and influence on outcome (2007) Eur J Haematol, 78 (3), pp. 213-219Dally, N., Hoffman, R., Haddad, N., Sarig, G., Rowe, J.M., Brenner, B., Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients (2005) Thromb Res, 116 (2), pp. 109-114Higuchi, T., Shimizu, T., Mori, H., Niikura, H., Omine, M., Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia (1997) Hematol Oncol, 15 (4), pp. 209-217Sanz, M.A., Lo Coco, F., Martín, G., Avvisati, G., Rayón, C., Barbui, T., Definition ofrelapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups (2000) Blood, 96 (4), pp. 1247-1253Huang, H., Qin, Y., Xu, R., You, X., Teng, R., Yang, L., Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks (2012) Leuk Res, 36 (7), pp. 841-845Candoni, A., Damiani, D., Michelutti, A., Masolini, P., Michieli, M., Michelutti, T., Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia (2003) Eur J Haematol, 71 (1), pp. 1-8Sanz, M.A., Montesinos, P., Vellenga, E., Rayón, C., de la Serna, J., Parody, R., Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA99 multicenter study by the PETHEMA Group (2008) Blood, 112 (8), pp. 3130-3134Kawai, Y., Watanabe, K., Kizaki, M., Murata, M., Kamata, T., Uchida, H., Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia (1994) Am J Hematol, 46 (3), pp. 184-188Rego, E.M., Kim, H.T., Ruiz-Argüelles, G.J., Undurraga, M.S., Uriarte, M.R., Jacomo, R.H., Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL (2013) Blood, 121 (11), pp. 1935-1943Drapkin, R.L., Gee, T.S., Dowling, M.D., Arlin, Z., McKenzie, S., Kempin, S., Prophylactic heparin therapy in acute promyelocytic leukemia (1978) Cancer, 41 (6), pp. 2484-2490Tallman, M.S., Kwaan, H.C., Reassessing the hemostatic disorder associated with acute promyelocytic leukemia (1992) Blood, 79 (3), pp. 543-553Zhao, W., Wang, X., Guo, W., Qu, B., Wang, H., Shen, Z., Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-transretinoic acid or arsenic trioxide treatment (2000) Chin Med J (Engl), 113 (3), pp. 236-240Escudier, S.M., Kantarjian, H.M., Estey, E.H., Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid (1996) Leuk Lymphoma, 20 (5-6), pp. 435-439Goldberg, M.A., Ginsburg, D., Mayer, R.J., Stone, R.M., Maguire, M., Rosenthal, D.S., Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? (1987) Blood, 69 (1), pp. 187-191Hoyle, C.F., Swirsky, D.M., Freedman, L., Hayhoe, F.G., Beneficial effect of heparin in the management of patients with APL (1988) Br J Haematol, 68 (3), pp. 283-289Bernard, J., Weil, M., Boiron, M., Jacquillat, C., Flandrin, G., Gemon, M.F., Acute promyelocytic leukemia: Results of treatment with daunorubicin (1973) Blood, 41 (4), pp. 489-496Lengfelder, E., Hanfstein, B., Haferlach, C., Braess, J., Krug, U., Spiekermann, K., Outcome of elderly patients with acute promyelocytic leukemia: Results of the German Acute Myeloid Leukemia Cooperative Group (2013) Ann Hematol, 92 (1), pp. 41-52Iland, H., Bradstock, K., Seymour, J., Hertzberg, M., Grigg, A., Taylor, K., Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia (2012) Haematologica, 97 (2), pp. 227-234Avvisati, G., Lo-Coco, F., Paoloni, F.P., Petti, M.C., Diverio, D., Vignetti, M., AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance (2011) Blood, 117 (18), pp. 4716-4725Adès, L., Guerci, A., Raffoux, E., Sanz, M., Chevalier, P., Lapusan, S., Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans-retinoic acid and chemotherapy: The European Group APL experience (2010) Blood, 115 (9), pp. 1690-1696Pagnano, K.B., de Carvalho, D.G., Lorand-Metze, I., Delamain, M.T., Miranda, E.C., de Souza, C.A., Treatment outcome of acute promyelocytic leukemia with modified aida protocol (2010) Adv Hematol, 2010, p. 672137Shen, Z.X., Shi, Z.Z., Fang, J., Gu, B.W., Li, J.M., Zhu, Y.M., All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia (2004) Proc Natl Acad Sci U S A, 101 (15), pp. 5328-5335Wang, H., Chen, X.Y., Wang, B.S., Rong, Z.X., Qi, H., Chen, H.Z., The efficacy and safety of arsenic trioxide with or without alltrans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-analysis (2011) Leuk Res, 35 (9), pp. 1170-1177Elemam, O., Abdelmoety, D., Acute promyelocytic leukemia, study of predictive factors for Differentiation Syndrome, single center experience (2013) J Egypt Natl Canc Inst, 25 (1), pp. 13-19Breccia, M., Mazzarella, L., Bagnardi, V., Disalvatore, D., Loglisci, G., Cimino, G., Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols (2012) Blood, 119 (1), pp. 49-54de Botton, S., Dombret, H., Sanz, M., Miguel, J.S., Caillot, D., Zittoun, R., Incidence, clinical features, and outcome of all transretinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group (1998) Blood, 92 (8), pp. 2712-2718Su, Y.C., Dunn, P., Shih, L.Y., Kuo, M.C., Chang, H., Wu, J.H., Retinoic acid syndrome in patients following the treatment of acute promyelocytic leukemia with all-trans retinoic acid (2009) Chang Gung Med J, 32 (5), pp. 535-542Jeddi, R., Ghédira, H., Mnif, S., Gouider, E., Fenaux, P., Meddeb, B., High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia (2010) Leuk Res, 34 (4), pp. 545-547Montesinos, P., Bergua, J.M., Vellenga, E., Rayón, C., Parody, R., de la Serna, J., León, A., Sanz, M.A., Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors (2009) Blood, 113 (4), pp. 775-783Jeddi, R., Kacem, K., Ben Neji, H., Mnif, S., Gouider, E., Aissaoui, L., Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia (2008) Hematology, 13 (3), pp. 142-146Montesinos, P., Sanz, M., The differentiation syndrome in patients with acute promyelocytic leukemia: Experience of pethema group and review of the literature (2011) Mediterr J Hematol Infect Dis, 3 (1), pp. e2011059Sastre, A., Gago, E., Baños, M., Gómez, E., Acute renal failure in the transretinóico syndrome (2007) Nefrologia, 27 (2), pp. 184-190Vahdat, L., Maslak, P., Miller Jr., W.H., Eardley, A., Heller, G., Scheinberg, D.A., Early mortalidade and the the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low dose-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patient treated with all-trans retinoic acid (1994) Blood, 84 (11), pp. 3843-3849Wiley, J.S., Firkin, F.C., Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukemia Study Group (1995) Leukemia, 9 (5), pp. 774-778Sanz, M.A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., Risk-adapted treatament of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome (2010) Blood, 115 (25), pp. 5137-5146de la Serna, J., Montesinos, P., Vellenga, E., Rayón, C., Parody, R., León, A., Causes e prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarrubicin (2008) Blood, 111 (7), pp. 3395-3402Tiamkao, S., Sirijirachai, C., Pseudotumor cerebri caused by all-trans-retinoic acid: A case report (2000) J Med Assoc Thai, 83 (11), pp. 1420-1423Mahmoud, H.H., Hurwitz, C.A., Roberts, W.M., Santana, V.M., Ribeiro, R.C., Krance, R.A., Tretinoin toxicity in children with acute promyelocytic leukaemia (1993) Lancet, 342 (8884), pp. 1394-1395Selleri, C., Pane, F., Notaro, R., Catalano, L., Santoro, L.E., Luciano, L., All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri (1996) Br J Haematol, 92 (4), pp. 937-940Visani, G., Bontempo, G., Manfroi, S., Pazzaglia, A., D'Alessandro, R., Tura, S., All-trans-retinoic acid and pseudotumor cerebri in a young adult with acute promyelocytic leukemia: A possible disease association (1996) Haematologica, 81 (2), pp. 152-154Chen, H.Y., Tsai, R.K., Huang, S.M., ATRA-induced pseudotumour cerebri--one case report (1998) Kaohsiung J Med Sci, 14 (1), pp. 58-60Sano, F., Tsuji, K., Kunika, N., Takeuchi, T., Oyama, K., Hasegawa, S., Pseudotumor cerebri in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid (1998) Intern Med, 37 (6), pp. 546-549Naderi, S., Nukala, S., Marruenda, F., Kudarvalli, P., Koduri, P.R., Pseudotumour cerebri in acute promyelocytic leukemia: Improvement despite continued ATRA therapy (1999) Ann Hematol, 78 (7), pp. 333-334Galm, O., Fabry, U., Osieka, R., Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide (2000) Leukemia, 14 (2), pp. 343-344Colucciello, M., Pseudotumor cerebri induced by all-trans retinoic acid treatment of acute promyelocytic leukemia (2003) Arch Ophthalmol, 121 (7), pp. 1064-1065Yeh, Y.C., Tang, H.F., Fang, I.M., Pseudotumor cerebri caused by all-trans-retinoic acid treatment for acute promyelocytic leukemia (2006) Jpn J Ophthalmol, 50 (3), pp. 295-296Dixon, K.S., Hassoun, A., Pseudotumor cerebri due to the potentiation of all-trans retinoic acid by voriconazole (2010) J Am Pharm Assoc (2003), 50 (6), pp. 742-744Machner, B., Neppert, B., Paulsen, M., Hofmann, C., Sander, T., Helmchen, C., Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid treatment in acute promyelocytic leukaemia (2008) Eur J Neurol, 15 (7), pp. e68-e69Gallipoli, P., Drummond, M.W., Pseudotumour cerebri as a manageable side effect of prolonged all-trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia (2009) Eur J Haematol, 82 (3), pp. 242-243Schroeter, T., Lanvers, C., Herding, H., Suttorp, M., Pseudotumor cerebri induced by all-trans-retinoic acid in a child treated for acute promyelocytic leukemia (2000) Med Pediatr Oncol, 34 (4), pp. 284-286Decaudin, D., Adams, D., Naccache, P., Castagna, L., Munck, J.N., Maintained all-trans retinoic acid therapy in a patient with pseudotumour cerebri despite aggravated symptoms (1997) Leuk Lymphoma, 27 (3-4), pp. 373-374Specchia, G., Lo Coco, F., Vignetti, M., Avvisati, G., Fazi, P., Albano, F., Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: A report by the Gruppo Italiano Malattie Ematologiche dell'Adulto (2001) J Clin Oncol, 19 (20), pp. 4023-4028Kakimoto, T., Takahashi, Y., Watanabe, H., Matsuzawa, M., Sanada, Y., Primary multiple cerebral invasion in acute promyelocytic leukemia dramatically worsened by all-trans retinoic acid (2010) Leuk Res, 34 (5), pp. e137-e139de Botton, S., Sanz, M.A., Chevret, S., Dombret, H., Martin, G., Thomas, X., Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy (2006) Leukemia, 20 (1), pp. 35-41Adès, L., Sanz, M.A., Chevret, S., Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results (2007) Epub, p. 1Adès, L., Chevret, S., Raffoux, E., de Botton, S., Guerci, A., Pigneux, A., Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group (2006) J Clin Oncol, 24 (36), pp. 5703-5710Sanz, M.A., Vellenga, E., Rayón, C., Díaz-Mediavilla, J., Rivas, C., Amutio, E., All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia (2004) Blood, 104 (12), pp. 3490-3493Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group (1999) Blood, 94 (4), pp. 1192-1200Sanz, M.A., Montesinos, P., Rayón, C., Holowiecka, A., de la Serna, J., Milone, G., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome (2010) Blood, 115 (25), pp. 5137-5146Schlenk, R.F., Germing, U., Hartmann, F., Glasmacher, A., Fischer, J.T., Valle, D., Fuentes, F., High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia (2005) Leukemia, 19 (6), pp. 978-983de Botton, S., Fawaz, A., Chevret, S., Dombret, H., Thomas, X., Sanz, M., Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group (2005) J Clin Oncol, 23 (1), pp. 120-126Sanz, M.A., Labopin, M., Gorin, N.C., de la Rubia, J., Arcese, W., Meloni, G., Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: A survey of the European Cooperative Group for Blood and Marrow Transplantation (2007) Bone Marrow Transplant, 39 (8), pp. 461-469Dvorak, C.C., Agarwal, R., Dahl, G.V., Gregory, J.J., Feusner, J.H., Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia (2008) Biol Blood Marrow Transplant, 14 (7), pp. 824-830Apperley, J., Carreras, E., Gluckman, E., Masszi, T., Hematopoietic Stem Cell Transplantation (2012) The EBMT HandbookChendamarai, E., Balasubramanian, P., George, B., Viswabandya, A., Abraham, A., Ahmed, R., Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy (2012) Blood, 119 (15), pp. 3413-3419Polampalli, S., Choughule, A., Prabhash, K., Amare, P., Baisane, C., Kabre, S., Role of RT-PCR and FISH in diagnosis and monitoring of acute promyelocytic leukemia (2011) Indian J Cancer, 48 (1), pp. 60-67Lee, S., Kim, Y.J., Eom, K.S., Min, C.K., Kim, H.J., Cho, S.G., The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RARalpha-positive acute promyelocytic leukemia: Results of a prospective trial (2006) Haematologica, 91 (5), pp. 671-674Liu, Y.F., Zhu, Y.M., Shen, S.H., Shen, Z.X., Li, J.M., Chen, S.J., Molecular response in acute promyelocytic leukemia: A direct comparison of regular and real-time RT-PCR (2006) Leukemia, 20 (8), pp. 1393-1399Santamaría, C., Chillón, M.C., Fernández, C., Martín-Jiménez, P., Balanzategui, A., García, S.R., Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia (2007) Haematologica, 92 (3), pp. 315-322Raffoux, E., Rousselot, P., Poupon, J., Daniel, M.T., Cassinat, B., Delarue, R., Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia (2003) J Clin Oncol, 21 (12), pp. 2326-2334Carradice, D., Austin, N., Bayston, K., Ganly, P.S., Successful treatment of acute promyelocytic leukaemia during pregnancy (2002) Clin Lab Haematol, 24 (5), pp. 307-311Yang, D., Hladnik, L., Treatment of acute promyelocytic leukemia during pregnancy (2009) Pharmacotherapy, 29 (6), pp. 709-724Watanabe, R., Okamoto, S., Moriki, T., Kizaki, M., Kawai, Y., Ikeda, Y., Treatment of acute promyelocytic leukemia with all-trans retinoic acid during the third trimester of pregnancy (1995) Am J Hematol, 48 (3), pp. 210-211Requena, A., Velasco, J.G., Pinilla, J., Gonzalez-Gonzalez, A., Acute leukemia during pregnancy: Obstetric management and perinatal outcome of two cases (1995) Eur J Obstet Gynecol Reprod Biol, 63 (2), pp. 139-141Incerpi, M.H., Miller, D.A., Posen, R., Byrne, J.D., All-trans retinoic acid for the treatment of acute promyelocytic leukemia in pregnancy (1997) Obstet Gynecol, 89 (5 PART 2), pp. 826-828Giagounidis, A.A., Beckmann, M.W., Giagounidis, A.S., Aivado, M., Emde, T., Germing, U., Acute promyelocytic leukemia and pregnancy (2000) Eur J Haematol, 64 (4), pp. 267-271Fadilah, S.A., Hatta, A.Z., Keng, C.S., Jamil, M.A., Singh, S., Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid (2001) Leukemia, 15 (10), pp. 1665-1666Nakamura, K., Dan, K., Iwakiri, R., Gomi, S., Nomura, T., Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid (1995) Ann Hematol, 71 (5), pp. 263-264Lipovsky, M.M., Biesma, D.H., Christiaens, G.C., Petersen, E.J., Successful treatment of acute promyelocytic leukaemia with all-trans-retinoic-acid during late pregnancy (1996) Br J Haematol, 94 (4), pp. 699-701Terada, Y., Shindo, T., Endoh, A., Watanabe, M., Fukaya, T., Yajima, A., Fetal arrhythmia during treatment of pregnancy-associated acute promyelocytic leukemia with all-trans retinoic acid and favorable outcome (1997) Leukemia, 11 (3), pp. 454-455Takitani, K., Hino, N., Terada, Y., Kurosawa, Y., Koh, M., Inoue, A., Plasma all-trans retinoic acid level in neonates of mothers with acute promyelocytic leukemia (2005) Acta Haematol, 114 (3), pp. 167-169Culligan, D.J., Merriman, L., Kell, J., The management of acute promyelocytic leucemia presenting during pregnancy (2007) Clin Leukemia, 1, pp. 183-191Cardonick, E., Iacobucci, A., Use of chemotherapy during human pregnancy (2004) Lancet Oncol, 5 (5), pp. 283-291Siu, B.L., Alonzo, M.R., Vargo, T.A., Fenrich, A.L., Trasient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans retinoic acid (ATRA) early in the second trimester of pregnancy (2002) Int J Gynecol Cancer, 12 (4), pp. 399-402Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., All-trans retinoic acid in acute promyelocytic leukemia (1997) N Engl J Med, 337 (15), pp. 1201-1208Latagliata, R., Avvisati, G., Lo Coco, F